Advanced searches left 3/3

Allergic Rhinitis - Springer Nature

Summarized by Plex Scholar
Last Updated: 04 August 2022

* If you want to update the article please login/register

Increased miR-124-3p alleviates type 2 inflammatory response in allergic rhinitis via IL-4Rα

However, miR-124-3p's effect on type 2 inflammation in allergic rhinitis is uncertain. We wanted to investigate miR-124-3p in AR and the mechanisms involved. Methods of Reporting MiR-124-3p and IL-4Ru03b1 was discovered by a dual-luciferase reporter assay, assay. In vitro splenic lymphocytes from mice and peripheral blood mononuclear cells from healthy people were cultured and treated with miR-124-3p mimic/inhibitor. Based on the number of sneezing and nasal scratching, the serum HDM-specific IgE levels, and the degree of nasal mucosa eosinophil infiltration, allergic reactions were analyzed. In both mouse splenic lymphocytes and human PBMCs in vitro, the miR-124-3p inhibitor restored these changes to the IL-4R03b1, p-STAT6, IL-4, IL-5, and IL-13 expression levels, although the miR-124-3p inhibitor rescued these changes. MiR-124-3p can reduce type 2 inflammation in AR by regulating IL-4R-u03b1 signaling, and miR-124-3p could be a promising new AR treatment target.

Source link: https://doi.org/10.1007/s00011-022-01614-x


The prevalence of complementary and alternative medicines (CAM) usage among allergic rhinitis patients in Malaysia

Purpose This research was conducted in Malaysia to determine the prevalence of complementary and alternative medicines use among allergic rhinitis patients and determine the use of CAM among them. Methods An cross-sectional research that included a questionnaire-based research and data of allergic rhinitis in patientu2019s clinic records included a questionnaire-based research and reports of allergic rhinitis from patientu2019s clinic records was included in this cross-sectional analysis. Patients with AR who attended the ORL-HNS department in Hospital Universiti Sains Malaysia and Hospital Sultanah Aminah, Malaysia, were recruited after consented, on a first-come first-serve basis as convenience sampling from July 2020 to February 2021. The questionnaire contains a series of 16 questions with subsets to investigate the sociodemographic use of CAM and its effectiveness. In the last ten years, 231 people had used CAM for AR for the first time. Conclusion CAM is widely used in Malaysia to alleviate AR symptoms, with a vast number of users agree it is safe.

Source link: https://doi.org/10.1007/s00405-021-07197-3


An anti-inflammatory and anti-fibrotic proprietary Chinese medicine nasal spray designated as Allergic Rhinitis Nose Drops (ARND) with potential to prevent SARS-CoV-2 coronavirus infection by targeting RBD (Delta)- angiotensin converting enzyme 2 (ACE2) binding

Background Since the epidemic of COVID-19 has resulted in over 313,000,000 confirmed cases of disease and over 5,500,000 deaths, over 5,500,000 people have died, extensive research has been done to find agents/ vaccines against COVID-19. An increasing number of direct evidence based on clinical trials of traditional Chinese medicines in the treatment of COVID-19 has been reported. Conclusions The results indicated that ARND not only decreased pseudovirus infection and undermined the Spike protein's binding affinity, but also attenuated the inflammatory reaction against infection, which may lead to a reduced risk of pulmonary fibrosis. In vivo and COVID-19 patients, the results in this study also point to further development of ARND as an antiviral hygienic drug and further studies on ARND as an antiviral hygienic drug. Conclusion ARND can be used as a safe anti-SARS-CoV-2 agent with the ability to fight SARS-CoV-2 coronavirus infection.

Source link: https://doi.org/10.1186/s13020-022-00635-2


Characteristics of IgG4-related disease complicated with allergic rhinitis or chronic rhinosinusitis: a large cross-sectional cohort study

Patients with allergic rhinitis/chronic rhinosinusitis were found to have particular characteristics different from patients with IgG4-RD alone, in clinical practice. We retrospectively reviewed 756 IgG4-RD patients who were recruited in four medical centers from 2009 to 2021. Patients with AR/CRS were divided into two groups, and the control group included IgG4-RD patients with AR/CRS, while the control group included IgG4-RD patients without AR/CRS. Patients in the case group had a higher serum IgG4, IgE, and ESR. Patients in the case group, in which most patients had nasal symptoms before diagnosis of IgG4-RD, had high IgE levels and other forms of allergic disease. Patients with AR and CRS were categorized as patients with nasal symptoms to IgG4-RD diagnosis, respectively.

Source link: https://doi.org/10.1038/s41598-022-15398-x


Bicalutamide, an androgen receptor antagonist, effectively alleviate allergic rhinitis via suppression of PI3K–PKB activity

Mice in Bica#1's Bica#1 group were intraperitoneally injected with 0. 02 mg Bicalutamide/0. 5 ml of normal saline every day for seven days; mice in the Bica#2 group were administered 0. 02 mg Bicalutamide/0. 5 ml of normal saline by intraperitoneal injection for five days, and then the same amount of normal saline was intraperitoneally for two days; mice in Bical injection intraperitone in Bica#1 group were intraperitonesaline were intraperitonetamide/0. 5 injected intraperitone borail def ml of Bical saline for 7 ml of Bical injection of BICA#1 group were sad'saline debical ml of Bical saline sa saline in Bical sa sad'sa ml of Bical sa Mice injected with 0. 02 mg Bicalutamide every day for 7 days as a result of the allergic lesion; however, mice treated with the same amount of normal saline at the same time showed no allergic rhinitis symptoms at the same time. Following two different dosages of Bicalutamide therapy in comparison to the OVA group, p-PKB protein levels were also reduced after two different dosages of Bicalutamide therapy, affecting the OVA group. Conclusions Our results revealed that androgen receptor antagonist Bicalutamide could effectively prevent allergic rhinitis lesion in the animal model.

Source link: https://doi.org/10.1007/s00405-022-07538-w


Effectiveness and safety of allergen immunotherapy in patients with allergic rhinitis complicated by rheumatic autoimmune diseases: a case series study

History Allergen immunotherapy is the only therapy that has changed allergic disease's natural history. Patients with RADs receiving AIT have no long-term studies; therefore, the safety and effectiveness of AIT in these patients remain unclear. Weak rhinitis patients attending AIT for allergic rhinitis at our hospital were chosen among our RAD patients. RAD patients' recruitment in the 2 years from baseline was investigated for two years, including those who stopped AIT. The signs of RADs in three patients worsened during the observation period for the third year in totality; however, none of them were causally connected to AIT. In the 2nd year of therapy, the patient's AIT, eye and nasal symptom scores increased from 1. 67 at baseline to 0. 67 in the nine patients who were able to continue AIT. AIT is a safe and effective treatment modality for patients with allergic rhinitis complicated by RADs.

Source link: https://doi.org/10.1186/s13223-022-00703-0


Sensitisation profile of Chinese allergic rhinitis patients and effectiveness of a joint allergy-ENT clinic

The most common cause of allergic rhinitis in Hong Kong is dust mite, but it is under-diagnosed and untreated. Patient-reported success measures and nasoendoscopy findings for AR have also not been investigated. Through the first allergistu2013otorhinolaryngologists joint clinic in Hong Kong, the first allergistu2013otorhinolaryngologists, sensitization patterns, quality of life, use of sublingual immunotherapy, and the association of PROMs and nasoendoscopy results in AR patients. The prevalence of HDM allergens, change in PROMs, and the association of PROMs with nasoendoscopy results were determined by clinical data from AR patients attending the ARJ clinic to determine the correlation of nasoendoscopy findings. The ARJ clinic in particular has significantly improved AR signs. When resources were limited, testing for Dermatophagoides pterynosinus as a single agent during skin testing was adequate for the diagnosis of HDM AR and should be prioritized.

Source link: https://doi.org/10.1007/s40629-022-00218-5

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions